Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2015 5
2016 9
2017 4
2018 8
2019 6
2020 3
2021 7
2022 8
2023 9
2024 18
2025 22
2026 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Results by year

Filters applied: . Clear all
Page 1
Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole.
Yang E, Kim S, Kim B, Kim B, Kim Y, Park SS, Song GS, Yu KS, Jang IJ, Lee S. Yang E, et al. Br J Clin Pharmacol. 2022 Jul;88(7):3288-3296. doi: 10.1111/bcp.15268. Epub 2022 Feb 23. Br J Clin Pharmacol. 2022. PMID: 35146797 Free PMC article. Clinical Trial.
This study was aimed to compare night-time acid suppression by tegoprazan with that by vonoprazan or esomeprazole, and to explore the effect of CYP2C19 phenotypes on acid-suppressive effects. ...CONCLUSION: Tegoprazan produced more rapid, potent …
This study was aimed to compare night-time acid suppression by tegoprazan with that by vonoprazan or esomeprazole, and …
Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments.
Scarpignato C, Hunt RH. Scarpignato C, et al. Curr Gastroenterol Rep. 2024 Nov;26(11):273-293. doi: 10.1007/s11894-024-00939-3. Epub 2024 Aug 15. Curr Gastroenterol Rep. 2024. PMID: 39145848 Free PMC article. Review.
PURPOSE OF THE REVIEW: Acid suppression with proton pump inhibitors (PPIs) represents the standard of care in the treatment of acid-related diseases. ...The failure to address these needs is mainly due to their inability to achieve a consistent acid …
PURPOSE OF THE REVIEW: Acid suppression with proton pump inhibitors (PPIs) represents the standard of care in the treatment of …
The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
Echizen H. Echizen H. Clin Pharmacokinet. 2016 Apr;55(4):409-18. doi: 10.1007/s40262-015-0326-7. Clin Pharmacokinet. 2016. PMID: 26369775 Review.
Being a base with pKa of 9.6 and with acid-resistant properties, vonoprazan is highly concentrated in the acidic canaliculi of the gastric parietal cells and elicited an acid suppression effect for longer than 24 h after the administration of 20 …
Being a base with pKa of 9.6 and with acid-resistant properties, vonoprazan is highly concentrated in the acidic canaliculi of …
Vonoprazan: A Review in Helicobacter pylori Infection.
Shirley M. Shirley M. Drugs. 2024 Mar;84(3):319-327. doi: 10.1007/s40265-023-01991-5. Epub 2024 Feb 23. Drugs. 2024. PMID: 38388872 Free PMC article. Review.
However, treatment success rates with current guideline-recommended proton-pump inhibitor (PPI)-based regimens remain suboptimal, with one potential factor associated with treatment failure being inadequate acid suppression. Vonoprazan (Voquezna( )) is a firs …
However, treatment success rates with current guideline-recommended proton-pump inhibitor (PPI)-based regimens remain suboptimal, with one p …
A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis.
Simadibrata DM, Syam AF, Lee YY. Simadibrata DM, et al. J Gastroenterol Hepatol. 2022 Dec;37(12):2217-2228. doi: 10.1111/jgh.16017. Epub 2022 Oct 26. J Gastroenterol Hepatol. 2022. PMID: 36181401 Free PMC article.
The current systematic review and meta-analysis aimed to compare the efficacy and safety of PCAB versus PPI in treating gastric acid-related diseases. METHODS: We searched up to June 5, 2022, for randomized controlled trials of gastric acid-related dis …
The current systematic review and meta-analysis aimed to compare the efficacy and safety of PCAB versus PPI in treating gastric ac …
Evaluation of gastric acid suppression with vonoprazan using calcium carbonate breath test.
Miyamoto S, Tsuda M, Kato M, Mabe K, Muto S, Ono S, Shimizu Y, Sakamoto N. Miyamoto S, et al. J Clin Biochem Nutr. 2019 Mar;64(2):174-179. doi: 10.3164/jcbn.18-75. Epub 2018 Nov 28. J Clin Biochem Nutr. 2019. PMID: 30936631 Free PMC article.
Vonoprazan, a potassium-competitive acid blocker, is a new class of acid-suppressing agent. The acid-inhibitory effect of vonoprazan has been well-documented. However, there is no report on the extent to which the amount of gastric …
Vonoprazan, a potassium-competitive acid blocker, is a new class of acid-suppressing agent. The acid-inhi …
The Role of P-CABs in GERD.
Howden CW. Howden CW. Am J Gastroenterol. 2025 May 1;120(5):993-998. doi: 10.14309/ajg.0000000000003140. Epub 2024 Oct 17. Am J Gastroenterol. 2025. PMID: 39466255 Review.
Potassium-competitive acid blockers (P-CABs) constitute a relatively new class of gastric acid-suppressing drugs. Among this class, vonoprazan is the first to have been approved in the United States. However, some P-CABs including vonoprazan …
Potassium-competitive acid blockers (P-CABs) constitute a relatively new class of gastric acid-suppressing drugs …
Vonoprazan: A Review in Erosive Esophagitis and Non-Erosive Gastro-Esophageal Reflux Disease.
Fung S. Fung S. Drugs. 2025 Jul;85(7):945-955. doi: 10.1007/s40265-025-02193-x. Epub 2025 May 19. Drugs. 2025. PMID: 40388079 Review.
If left untreated, it can increase the risk of serious complications through to esophageal cancer. GERD is treated with gastric acid-suppressing agents; however, patients can relapse or have incomplete symptom relief with traditional treatments. Vonoprazan …
If left untreated, it can increase the risk of serious complications through to esophageal cancer. GERD is treated with gastric ac …
Effects of pirenzepine on vonoprazan-induced gastric acid inhibition and hypergastrinemia.
Suzuki T, Higuchi T, Kagami T, Uotani T, Yamade M, Tani S, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Furuta T. Suzuki T, et al. Eur J Clin Pharmacol. 2021 Jul;77(7):971-978. doi: 10.1007/s00228-021-03162-5. Epub 2021 May 31. Eur J Clin Pharmacol. 2021. PMID: 34059932 Clinical Trial.
BACKGROUND: Compared to proton pump inhibitors, vonoprazan exerts a greater inhibitory effect on gastric acid secretion and is useful for treating acid-related diseases, such as gastro-esophageal reflux disease. ...Here, we examined whether pirenzepine …
BACKGROUND: Compared to proton pump inhibitors, vonoprazan exerts a greater inhibitory effect on gastric acid secretion …
Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis.
Kanu JE, Soldera J. Kanu JE, et al. World J Gastroenterol. 2024 Mar 7;30(9):1213-1223. doi: 10.3748/wjg.v30.i9.1213. World J Gastroenterol. 2024. PMID: 38577188 Free PMC article.
While conventional proton pump inhibitor (PPI)-based triple therapy is effective, there's growing interest in longer acid suppression therapies. Potassium competitive acid blocker (P-CAB) triple and dual therapy are new regimens for H. pylori eradication. Ini …
While conventional proton pump inhibitor (PPI)-based triple therapy is effective, there's growing interest in longer acid suppress …
100 results